CA3163697A1 - Individualized dialysis with inline sensor - Google Patents
Individualized dialysis with inline sensorInfo
- Publication number
- CA3163697A1 CA3163697A1 CA3163697A CA3163697A CA3163697A1 CA 3163697 A1 CA3163697 A1 CA 3163697A1 CA 3163697 A CA3163697 A CA 3163697A CA 3163697 A CA3163697 A CA 3163697A CA 3163697 A1 CA3163697 A1 CA 3163697A1
- Authority
- CA
- Canada
- Prior art keywords
- dialysis
- individualized
- prescription
- patient
- prescriber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000502 dialysis Methods 0.000 title claims abstract description 314
- 238000011282 treatment Methods 0.000 claims abstract description 108
- 238000000034 method Methods 0.000 claims description 42
- 238000012549 training Methods 0.000 claims description 21
- 238000010801 machine learning Methods 0.000 claims description 14
- 238000012706 support-vector machine Methods 0.000 claims description 12
- 238000013473 artificial intelligence Methods 0.000 claims description 11
- 239000003792 electrolyte Substances 0.000 description 157
- 210000004369 blood Anatomy 0.000 description 63
- 239000008280 blood Substances 0.000 description 63
- 239000000126 substance Substances 0.000 description 57
- 238000001631 haemodialysis Methods 0.000 description 51
- 230000000322 hemodialysis Effects 0.000 description 51
- 238000002156 mixing Methods 0.000 description 48
- 239000000203 mixture Substances 0.000 description 45
- 238000005259 measurement Methods 0.000 description 42
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 37
- 239000011734 sodium Substances 0.000 description 37
- 229910052708 sodium Inorganic materials 0.000 description 37
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 25
- 239000011591 potassium Substances 0.000 description 25
- 229910052700 potassium Inorganic materials 0.000 description 25
- 235000008504 concentrate Nutrition 0.000 description 23
- 239000012141 concentrate Substances 0.000 description 23
- 230000008569 process Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000013500 data storage Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000011575 calcium Substances 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012503 blood component Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013135 deep learning Methods 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000014666 liquid concentrate Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021036 Hyponatraemia Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940021013 electrolyte solution Drugs 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000019948 ion homeostasis Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940100060 combination of electrolytes Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000036514 plasma sodium concentration Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1613—Profiling or modelling of patient or predicted treatment evolution or outcome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
- A61M1/36225—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit with blood pumping means or components thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967349P | 2020-01-29 | 2020-01-29 | |
| US62/967,349 | 2020-01-29 | ||
| US16/811,533 | 2020-03-06 | ||
| US16/811,533 US20200282125A1 (en) | 2019-03-07 | 2020-03-06 | Individualized dialysis with inline sensor |
| PCT/US2021/014828 WO2021154616A1 (en) | 2020-01-29 | 2021-01-24 | Individualized dialysis with inline sensor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3163697A1 true CA3163697A1 (en) | 2021-08-05 |
Family
ID=77079467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3163697A Pending CA3163697A1 (en) | 2020-01-29 | 2021-01-24 | Individualized dialysis with inline sensor |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4096743A4 (de) |
| CN (1) | CN114945393A (de) |
| AU (1) | AU2021213687A1 (de) |
| CA (1) | CA3163697A1 (de) |
| WO (1) | WO2021154616A1 (de) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8769625B2 (en) | 2011-11-17 | 2014-07-01 | Fresenius Medical Care Holdings, Inc. | Remote control of dialysis machines |
| US9597439B2 (en) * | 2013-03-15 | 2017-03-21 | Fresenius Medical Care Holdings, Inc. | Medical fluid sensing and concentration determination using radio frequency energy and a magnetic field |
| US10842926B2 (en) | 2015-01-14 | 2020-11-24 | Fresenius Medical Care Deutschland Gmbh | Medical fluid treatment machines and related systems and methods |
| CN105447305A (zh) * | 2015-11-12 | 2016-03-30 | 中国船舶重工集团公司第七一六研究所 | 可远程监控的腹膜透析系统及监控方法 |
| US10758659B2 (en) * | 2016-08-10 | 2020-09-01 | Medtronic, Inc. | Peritoneal dialysis filtrate sampling and adaptive prescription |
| US10623188B2 (en) | 2017-04-26 | 2020-04-14 | Fresenius Medical Care Holdings, Inc. | Securely distributing medical prescriptions |
| US11135345B2 (en) * | 2017-05-10 | 2021-10-05 | Fresenius Medical Care Holdings, Inc. | On demand dialysate mixing using concentrates |
| US11389575B2 (en) | 2017-07-14 | 2022-07-19 | Fresenius Medical Care Holdings, Inc. | Prescription compatibility checking for a medical device |
| CN111971755A (zh) | 2018-04-12 | 2020-11-20 | 费森尤斯医疗保健控股公司 | 用于确定透析患者的功能以评估姑息和/或临终护理的参数和定时的系统和方法 |
| US11229727B2 (en) * | 2019-08-07 | 2022-01-25 | Kata Gardner Technologies | Intelligent adjustment of dialysis machine operations |
-
2021
- 2021-01-24 AU AU2021213687A patent/AU2021213687A1/en not_active Abandoned
- 2021-01-24 CN CN202180008245.7A patent/CN114945393A/zh active Pending
- 2021-01-24 CA CA3163697A patent/CA3163697A1/en active Pending
- 2021-01-24 WO PCT/US2021/014828 patent/WO2021154616A1/en unknown
- 2021-01-24 EP EP21748401.3A patent/EP4096743A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN114945393A (zh) | 2022-08-26 |
| EP4096743A4 (de) | 2024-04-03 |
| AU2021213687A1 (en) | 2022-06-23 |
| WO2021154616A1 (en) | 2021-08-05 |
| EP4096743A1 (de) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11285248B2 (en) | Therapy prediction and optimization for renal failure blood therapy | |
| JP5505846B2 (ja) | 腹膜透析のための簡易化された腹膜平衡試験 | |
| AU2011304420B2 (en) | Obtaining control settings for a dialysis machine | |
| CN102159260B (zh) | 用于在肾脏替代治疗中早期预测Kt/V参数的方法和设备 | |
| US20120273354A1 (en) | Multimodal dialysis system | |
| EP3229159B1 (de) | Optimierung von serum-kalium zur bluttherapie bei nierenversagen, insbesondere heim-hämdialyse | |
| EP3281655A1 (de) | Adaptive peritonealdialyseflüssigkeitsentfernung zwischen sitzungen zur optimierung mehrerer sitzungen | |
| EP2558966B1 (de) | Therapieprognose und optimierung für bluttherapie bei nierenversagen, im besonderen hämodialyse | |
| US20220130527A1 (en) | Treatment Sharing Method Implemented on a Treatment Machine | |
| CN107715209B (zh) | 腹膜透析滤出液取样和自适应处方 | |
| US20200282125A1 (en) | Individualized dialysis with inline sensor | |
| US11806456B2 (en) | Precision peritoneal dialysis therapy based on dialysis adequacy measurements | |
| US20210233635A1 (en) | Individualized dialysis with inline sensor | |
| CA3163697A1 (en) | Individualized dialysis with inline sensor | |
| Azar | Adaptive neuro-fuzzy system as a novel approach for predicting post-dialysis urea rebound | |
| Poeppel et al. | Equipment commonly used in veterinary renal replacement therapy | |
| EP4184520A1 (de) | Plasma-elektrolyt-verwaltungssystem, verfahren und geräte für kontinuierliche nierenersatztherapien (rrt) | |
| ES2937293T3 (es) | Aparato para el tratamiento de sangre extracorpóreo | |
| KR20220018979A (ko) | 계산 기기 및 투석 장치 | |
| Everdell | A haemodialysis system for the treatment of acute renal failure and metabolic disorders in neonates | |
| AU2015203634B2 (en) | Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis | |
| WO2023129497A2 (en) | Personalized peritoneal dialysis treatment using design of experiment techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220908 |
|
| EEER | Examination request |
Effective date: 20220908 |
|
| EEER | Examination request |
Effective date: 20220908 |
|
| EEER | Examination request |
Effective date: 20220908 |